Loading...
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
OBJECTIVE: In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA(1c)], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood...
Na minha lista:
| Udgivet i: | Diabetes Care |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Diabetes Association
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7510043/ https://ncbi.nlm.nih.gov/pubmed/32816874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc19-1350 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|